Category: Oncotarget

Oncotarget News

Oncotarget

Oncotarget | Plasma Growth Hormone a Potential Biomarker of Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma Patients

December 22, 2022

In conclusion, our study demonstrate[s] that plasma GH represents a candidate biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev.”—BUFFALO, NY- December 22,... read more

“Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.”

Oncotarget

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

December 13, 2022

Dr. Kerri Winters-Stone and Dr. Jacob Raber from Oregon Health and Science University, describe a research paper they co-authored that was published by Oncotarget in Volume 13, entitled, “Association of... read more

Oncotarget

Oncotarget | Combined Epigenetic and Immunotherapy for Blastic and Classical Mantle Cell Lymphoma

December 13, 2022

Here, we describe results using cladribine based combination epigenetic and immunotherapy in MCL [mantle cell lymphoma].”BUFFALO, NY- December 13, 2022 – A new research paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget | Expression of p-STAT3 and c-Myc Correlates With P2-HNF4α Expression in Nonalcoholic Fatty Liver Disease (NAFLD)

December 6, 2022

In conclusion, our results suggest that STAT3 phosphorylation occurs in livers with NAFLD only in the subset with P2-HNF4α expression, and c-Myc expression is strongly correlated with STAT3 phosphorylation.”BUFFALO,... read more

Oncotarget

Oncotarget | Essential Amino Acids as Diagnostic Biomarkers of Hepatocellular Carcinoma Based on Metabolic Analysis

December 1, 2022

The current and previous findings provide a rationale for further investigations into the potential utility of leucine, valine, and tryptophan as diagnostic and prognostic biomarkers for HCC.”BUFFALO, NY- December... read more

Oncotarget

Oncotarget | Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

November 29, 2022

MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.”BUFFALO, NY- November 29, 2022 – A new review was published in Oncotarget's Volume 13... read more

Oncotarget

Oncotarget | Treasures From Trash in Cancer Research

November 23, 2022

Most of these supposed useless data are often treated as trash and remain unexplored. However, in some cases, treasures hidden in these data are discarded [2, 4].”BUFFALO, NY- November... read more

Oncotarget

Oncotarget | Association of Fall Rate and Functional Status by APOE Genotype in Cancer Survivors After Exercise Intervention

November 21, 2022

This is the first examination of the relationship among exercise, apoE genotype, and side effects and symptoms of cancer in a subset of older female cancer survivors participating in a... read more

Oncotarget

Oncotarget | Mutation Analysis Performed on Tumor Biopsies From Patients With Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas

November 17, 2022

Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS [disease free survival] following treatment with... read more

Oncotarget

Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway

November 10, 2022

In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.”BUFFALO, NY-... read more